Potentiating therapeutic effects of epidermal growth factor receptor inhibition in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive
characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a …
characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a …
[HTML][HTML] Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or …
Y Chen, S Wen, Y Wu, L Shi, X Xu, B Shen - Critical Reviews in Oncology …, 2021 - Elsevier
Objective We conducted a meta-analysis to synthesize the results of published randomized
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
[HTML][HTML] Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines
AS Alshetaili - Saudi journal of biological sciences, 2021 - Elsevier
In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan
coated PLGA nanoparticles (GFT-CS-PLGA-NPs) were synthesized to investigate the role of …
coated PLGA nanoparticles (GFT-CS-PLGA-NPs) were synthesized to investigate the role of …
Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-Mutant non–small cell lung Cancer in patients with brain metastases: the GAP BRAIN open-label …
X Hou, M Li, G Wu, W Feng, J Su, H Jiang… - JAMA network …, 2023 - jamanetwork.com
Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …
[HTML][HTML] Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from …
M Provencio, R Serna-Blasco, F Franco, V Calvo… - European Journal of …, 2021 - Elsevier
Background Survival data support the use of first-line osimertinib as the standard of care for
epidermal growth factor receptor (EGFR)–positive non-small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)–positive non-small cell lung cancer (NSCLC) …
Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer
Y Hu, J Zhang, H Hu, S Xu, L Xu, E Chen - Cell Cycle, 2020 - Taylor & Francis
Gefitinib (GEB) is one of the drugs used for patients with epidermal growth factor receptor
(EGFR)-positive mutations in non-small cell lung cancer (NSCLC). However, application of …
(EGFR)-positive mutations in non-small cell lung cancer (NSCLC). However, application of …
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic …
W Chen, J Miao, Y Wang, W Xing, X Xu… - Frontiers in …, 2023 - frontiersin.org
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
T Moriya, M Hamaji, A Yoshizawa… - Interactive …, 2022 - academic.oup.com
OBJECTIVES To clarify survival outcomes and prognostic factors of patients receiving
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) as first-line …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) as first-line …
First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of …
Y Tsukita, A Inoue - Japanese Journal of Clinical Oncology, 2022 - academic.oup.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been
established as the standard first-line treatment for patients with previously untreated …
established as the standard first-line treatment for patients with previously untreated …
Front‐Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non‐Small Cell Lung Cancer: A Network Meta‐Analysis
T Xie, Z Zou, C Liu, Y Zhu, Z Xu, L Wang… - Evidence‐Based …, 2021 - Wiley Online Library
Objective. This study aimed to compare the efficacy of different first‐line strategies based on
different EGFR mutation types (19 deletion and 21 Leu858Arg mutations). Methods. We …
different EGFR mutation types (19 deletion and 21 Leu858Arg mutations). Methods. We …